Key Requirements

Adults with any form of RP (i.e., regardless of genetic cause) qualified for the study based on the following key study requirements*:

• Age 18 - 60
• Confirmed diagnosis of retinitis pigmentosa
• Vision between 20/80 and 20/800 in the study eye
• Remaining central island visual field diameter should be at least 8° in the study eye
• No major poorly controlled general health issues other than retinitis pigmentosa
• Commitment to traveling to Irvine, CA three to four times over a 6-month period (reimbursement of travel expenses for study-related assessments is provided for participants and a companion)
• No prior participation in ANY clinical trial within the last 6 months EXCEPT for studies evaluating N-acetyl cysteine (NAC), in which case participation in this jCell study is still possible
• No history of OCULAR treatment with any non-approved, experimental retinal therapy (including jCell) or device in either eye except for NAC treatment, which must be stopped at least 7 days before joining the study
• Not pregnant or planning to become pregnant during the 6-month study period and for 6 months following the study – for a total of 12 months

For more details, please visit trial NCT06912633 on clinicaltrials.gov.

*The key requirements shown here represent critical eligibility criteria at a high level. Official study eligibility was determined based on the explicit and precise requirements contained in the protocol.

Follow-up

Patients participating in JC02-88 will be required to attend 10 in-person visits and have one remote phone call consultation over the 6-month study period. Three to four of the in-person visits will require travel to Irvine, CA. If the JC02-88 study results are positive, a subsequent follow-up (“extension”) study is planned (JC02-88E). The JC02-88E study will provide those who received the sham treatment the opportunity to receive jCell and have their eye health and vision changes monitored. Those who received jCell in the JC02-88 study will also have the opportunity to participate in the extension study for longer-term monitoring but will not receive a second jCell treatment.